Patent US3318292A successfully refreshed from Google Patents.
US4324686A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hematology control composition and methods for its use
Assignee: R & D SYSTEMS Inc A CORP OF MN
•
Filing: 1979-06-11
•
Granted: 1982-04-13
•
Expires: 1999-06-11
Abstract
Abstract A control blood platelet preparation containing a population of platelets of known count range, electronic volume and electronic volume size distribution is ued to check the threshold setting calibrations of an electronic particle counter. The control preparation preferably contains blood platelets from whole blood taken from animal species which are non-injectious with respect to human hepatitis, ideally animals of the bovine and porcine species.
Inventors
- 👤 David D. Mundschenk
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 07:28
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/96; G01N15/00; G01N15/10; G01N15/1031; G01N15/12; G01N15/131; G01N2496/00; G01N2496/05; Y; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/101666
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
61 words
A control blood platelet preparation comprising bovine or porcine blood platelets stabilized as to size and against surface aggregation and derived, respectively, from bovine or porcine platelet rich blood plasma, the platelets of the preparation being larger in size than, but substantially retaining the natural log-normal volume size distribution of, the platelet rich blood plasma from which the platelets were derived.
Claim 2
Dependent Claim
61 words
A control blood platelet preparation comprising bovine or porcine blood platelets stabilized as to size and against surface aggregation and derived, respectively, from bovine or porcine platelet rich blood plasma, the platelets of the preparation being larger in size than, but substantially retaining the natural log-normal volume size distribution of, the platelet rich blood plasma from which the platelets were derived.
Claim 3
Dependent Claim
20 words
A control blood platelet preparation according to claim 1 further comprising sufficient diluent to effect a known concentration of platelets.
Claim 4
Dependent Claim
34 words
A control blood platelet preparation according to claim 2, wherein said diluent is derived from the same whole blood source as the platelets, and comprises clarified supernatant plasma fluid diluted with aqueous saline solution.
Claim 5
Dependent Claim
21 words
A control blood platelet preparation according to claim 2, wherein said diluent includes up to about 30 volume percent propylene glycol.
Claim 6
Dependent Claim
46 words
A control blood platelet preparation according to claim 1 including first and second discreet sub-preparations, the first sub-preparation containing a population of platelets having a relatively large mean electronic volume, and the second sub-preparation containing a population of platelets having a relatively small mean electronic volume.
Claim 7
Dependent Claim
45 words
A control blood platelet preparation according to claim 5 wherein the mean electronic volume of said first sub-preparation is between about 5 fl and about 8 fl, and the mean electronic volume of said second sub-preparation is between about 10 fl and about 18 fl.
Claim 8
Dependent Claim
8 words
The control of claim 1 further comprising erythrocytes.
Claim 9
Independent Claim
60 words
A method for preparing a control blood preparation comprising: (a) Providing bovine or porcine platelet rich blood plasma; (b) Swelling the platelets of said plasma to a size within the size range corresponding to human blood platelets while substantially maintaining the natural log-normal platelet distribution; and (c) Stabilizing and fixing the platelets to inhibit surface aggregation and fix their size.
Claim 10
Independent Claim
60 words
A method for preparing a control blood preparation comprising: (a) Providing bovine or porcine platelet rich blood plasma; (b) Swelling the platelets of said plasma to a size within the size range corresponding to human blood platelets while substantially maintaining the natural log-normal platelet distribution; and (c) Stabilizing and fixing the platelets to inhibit surface aggregation and fix their size.
Claim 11
Dependent Claim
16 words
The method of claim 8 in which said swelling step includes contacting said platelets with urea.
Claim 12
Dependent Claim
42 words
The method of claim 8 wherein the stabilizing and fixing step compromises adding an effective amount of fixative below about one volume percent to cause cross-linking of proteins in the membrane of said platelets in the presence of protein in said plasma.
Claim 13
Dependent Claim
21 words
A method according to claim 10 wherein said fixative is selected from the group consisting of glutaraldehyde, formaldehyde and osmium tetroxide.
References Cited (Backward Citations)
US3406121A
Cited
US3876375A
Cited
US3876375B1
Cited
US4157383A
Cited
US4145185A
Cited
US4287087A
Cited
US4179398A
Cited
US4160644A
Cited
US4198206A
Cited
US4199471A
Cited
US4264470A
Cited
US4219440A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-04-12 | 1985-10-12 | 1986-04-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-04-12 | 1989-10-12 | 1990-04-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-04-12 | 1993-10-12 | 1994-04-13 | $7700.00 | Window Closed / Lapsed |